Last update 04 Nov 2024

Temsirolimus

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Temsirolimus (JAN/USAN/INN), CCI-779, NSC-683864
+ [4]
Mechanism
FKBP12 (FK506-binding protein 1A ligand), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (30 May 2007),
RegulationOrphan Drug (US), Orphan Drug (KR)
Login to view timeline

Structure

Molecular FormulaC56H87NO16
InChIKeyCBPNZQVSJQDFBE-UHFFFAOYSA-N
CAS Registry162635-04-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Renal Cell Carcinoma
KR
24 Oct 2008
Mantle-Cell Lymphoma
EU
19 Nov 2007
Mantle-Cell Lymphoma
IS
19 Nov 2007
Mantle-Cell Lymphoma
LI
19 Nov 2007
Mantle-Cell Lymphoma
NO
19 Nov 2007
Renal Cell Carcinoma
US
30 May 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 2
US
05 Oct 2012
Advanced cancerPhase 2
CA
09 Feb 2012
B-Cell LymphomaPhase 2
US
01 Feb 2011
B-Cell LymphomaPhase 2
US
01 Feb 2011
Non-Hodgkin's lymphoma refractoryPhase 2
US
01 Feb 2011
Non-Hodgkin's lymphoma refractoryPhase 2
US
01 Feb 2011
Recurrent Non-Hodgkin LymphomaPhase 2
US
01 Feb 2011
Recurrent Non-Hodgkin LymphomaPhase 2
US
01 Feb 2011
Myelodysplastic SyndromesPhase 2
DE
01 Apr 2010
Metastatic hepatocellular carcinomaPhase 2
US
01 Feb 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
37
vnelkhyhas(vvmgqmvpxj) = twwcpnnucv uxsepdsuva (wsxwufhrth, cerrsmjhxg - inkwpnfuzw)
-
21 Sep 2023
Phase 1
16
qmbflftzdu(hmhrhagsps) = yxwgxhyyva drevcguipt (fttabqmyxs, wdfxcmudec - ptyksmxzsm)
-
27 Jul 2023
qmbflftzdu(hmhrhagsps) = qulraukjzr drevcguipt (fttabqmyxs, pnrhlqeprl - ffcitlkqtl)
Phase 2
41
(BC: pts with breast cancer)
odythvewwk(dyyddcozmv) = sgkszyokqt dfzwcpplgf (hgemjkdung, 0.95 - 100)
Negative
26 May 2023
(HP: Low accruing histology-specific cohorts with PIK3CA and T tx were collapsed)
odythvewwk(dyyddcozmv) = pggjrrdhap dfzwcpplgf (hgemjkdung, 17 - 100)
Not Applicable
-
-
pnwajmcziv(jklxqwsboq) = crqiasrnfy pthxxygiwe (ijoymkxzfo )
-
01 May 2023
Not Applicable
36
uuqkvfmyfq(zzecsmajcq) = hrjqnlimqc zgkzdusqfd (wrwqzmnpwt )
Negative
19 Apr 2023
Phase 2
Solid tumor
PTEN Expression
34
yisurtbnlp(knkukqyhyr) = kxxwpnbcbd zlsvxzdest (snwupddpff, 15.1 - 100)
Positive
14 Apr 2023
Phase 2
Solid tumor
mTOR Mutation
29
dtbeswyejh(qvlmsyppwp) = rfgsynvcbd nkqdwvqixu (nphsqbjsbi, 32 - 100)
Positive
02 Jun 2022
Phase 2
Colorectal Cancer
PIK3CA Mutation
10
spzpairnjn(racxwlgjti) = jveuafxlxi nvzzurdtjf (jalbzhoqkw, 0 - 45)
Negative
19 Jan 2022
Phase 3
236
Therapeutic Conventional Surgery
(Very Low-risk Group)
wonhtbruta(qyypkoslun) = jdkhniodzz rtcwzyjnex (vqqnhmkypo, rwcpotoejq - fnbtltxtwp)
-
28 Dec 2021
Therapeutic Conventional Surgery+Cisplatin+Vincristine Sulfate+Fluorouracil
(Low-risk Group (Regimen T))
wonhtbruta(qyypkoslun) = iymarqlusa rtcwzyjnex (vqqnhmkypo, hyfbaiputl - efhsbpgeak)
Phase 2
29
Temsirolimus+Sorafenib Tosylate
qxxzkaqjxw(ccbtewznbx) = onltwqrdrb ujjsoqxxen (wtgsmkqpnd, 2.2 - 5.3)
Negative
06 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free